Influenza-like Illness Incidence Is Not Reduced by Influenza Vaccination Influenza vaccination reduces the number of influenza virus infections but not the overall number of illness.
Blood spot test extended as of 1 January 2017 to include two more disorders As of 1 January 2017, the disorders alpha and beta thalassaemia will be added to the neonatal blood spot (‘heel prick’) screening programme.
EFSA agrees with RIVM that potential effect of BPA on the immune system requires further attention RIVM expressed concerns on the effects of bisphenol a (BPA) on the immune system in a report issued in March 2016.
Moderate flu season Last winter season, the duration and severity of the influenza epidemic was moderate compared to previous years.
RIVM recommends more stringent EU standards BPA More stringent European standards for safe exposure of workers and consumers to bisphenol A (BPA) were proposed in 2014 and 2015.
Newborn heel prick screening starts on St Eustatius and Saba On 26 October 2015, heel prick screening started for all newborns on St Eustatius and Saba.
Flu season in the winter of 2014 / 2015 more severe and longer than preceding years The flu epidemic in the winter of 2014 / 2015 lasted 21 weeks and as such was the longest epidemic ever recorded in the Netherlands. Nearly two million people suffered from flu-like symptoms.
Biobased alternatives to hormone disrupting substance in cash register receipts Chemicals made from vegetable or animal waste may be an alternative to the use of the substance Bisphenol A (BPA) in thermal paper. Thermal paper is widely used for cash register receipts.
RIVM provides overview of the possible risks of bisphenol A RIVM has created an overview of the possible risks of Bisphenol A (BPA) for humans and the environment. BPA is a component of many different products and affects the endocrine system.